ClinicalTrials.gg
RecruitingNCT06274528Updated Jul 13, 2026

DORA and LP in Alzheimer's Disease Biomarkers

A Phase 2 interventional study of Lemborexant 10 mg and Lemborexant 20mg in Alzheimer Disease, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alzheimer Disease by University of Minnesota — 3 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University of Minnesota.

Planned enrollment
4th of 14
201 · median 162
Started
2024
with 1 other
Phase 2
3 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Alzheimer Disease by University of Minnesota, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 2, and was the 15th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 16 studies in Alzheimer Disease by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by University of Minnesota, or all of them as a file.
02

Study summary

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

Read the detailed description

The overall goal of this project is to conduct an early stage (phase II) clinical trial of a dual orexin receptor antagonist (DORA), lemborexant, in cognitively normal older adults with amyloid deposition to demonstrate the feasibility and potential biological effectiveness of lemborexant's target engagement with multiple blood plasma and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers. Orexins (also called hypocretins) are wake-promoting neuropeptides and blockade of orexin with a DORA increases sleep. The scientific premise of this project is that increased or enhanced sleep over 6 months by treatment with lemborexant will decrease the ratio of phosphorylated tau-181/tau-181 (pT181/T181) in blood and the concentration of CSF and plasma AD biomarkers (amyloid-β (Aβ), tau and phosphorylated tau (p-tau)) as well as neurodegeneration, inflammatory and synaptic AD biomarkers such as neurofilament light chain (NfL) (a non-tau marker of neuronal degeneration), soluble triggering receptor expressed on myeloid cells 2 (sTREM2) (a marker for immune response/microglial function), and neuronal pentraxin-2 (NPTX2) a marker for synaptic function) compared to placebo in amyloid-positive cognitively normal older adults. In addition, the investigators will also determine lemborexant's safety, pharmacokinetics (PK), and pharmacodynamics (PD) in this population. This study will enhance trial design and methods by providing critical information about dosing, safety, and target engagement of lemborexant on CSF and blood AD biomarkers to power phase III secondary prevention trials using lemborexant.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Sleep
  • Older Adults
  • DORA
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Any race or ethnicity.
  • Participants must be age ≥ 65 years and able to sign .
  • Global Clinical Dementia Rating (CDR) 0.
  • Willing and able to undergo study procedures.

Exclusion criteria

Exclusion Criteria:

  • History or reported symptoms suggestive of restless legs syndrome, narcolepsy, or parasomnia.
  • STOP-Bang score >6 for participants without PAP.
  • Untreated sleep apnea AHI>15
  • Poorly treated sleep apnea due to noncompliance or an AHI ≥ 10.

    - PAP compliance is defined as ≥ 4 hours per night >70% of the nights.

  • Plasma p-Tau217/np-Tau217% \<2.5
  • Stroke.
  • History of renal impairment

    • Defined as older adult patients with markers of kidney damage or \< 45.0 ml/min/1.73m2.
    • Normal Limits ≥ 45.0 mL/min/1.73m2
  • History of hepatic impairment

    • and/or ALT ≥ 2X (ULN).
    • Normal Limits: AST 11-47 IU/L and ALT 6-53 IU/L
  • /AIDS.
  • History of substance abuse or alcohol abuse in the preceding 6 months.
  • Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
  • History of presence of any medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
  • Has any medical condition that, in the PI's or study team investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's or study team investigator's discretion:

    • Cardiovascular disease requiring medication except for controlled hypertension.
    • Pulmonary disease.
    • Type I diabetes.
    • Neurologic or psychiatric disorder requiring medication.
    • Untreated depression
    • Tobacco use.
    • Use of sedating medications.
    • Use of medications that interact with lemborexant (if cannot be discontinued).
    • Abnormal safety labs.
  • History of current suicidal ideations.
  • Inability to speak and understand English.
  • Currently pregnant or breast-feeding.
  • In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
  • Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
  • Must not participate in another drug or device study prior to the end of this study participation.

Optional assessment exclusion criteria:

  • to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    Lemborexant 10 mg

    Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.

    Drug: Lemborexant 10 mg

  • Experimental
    Lemborexant 20 mg

    Lemborexant is a capsule, taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.

    Drug: Lemborexant 20mg

  • Placebo comparator
    Placebo

    Placebo is in capsule form and contains an inactive substance. It is taken by mouth once a night, approximately 30 minutes prior to bed for 6 months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Changes plasma pT181/T181 ratio of lemborexant 10 and 20 mg compared to Placebo

    plasma collection

    Time frame: 6 months

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Adverse events

    Time frame: 6 months

  2. Measure the blood concentration of lemborexant 10 mg and 20 mg and determine the dose-response relationship with CSF pT181/T181

    Blood collection

    Time frame: 6 months

  3. Measure changes on blood plasma amyloid-beta isoforms (Aβ38, Aβ40, Aβ42, Aβ42/Aβ40)

    Blood collection

    Time frame: 6 months

  4. Measure changes of CSF amyloid beta isoforms (Aβ38, Aβ40, Aβ42,Aβ42/Aβ40 )

    CSF collection

    Time frame: 6 months

  5. Measure changes of blood plasma p-tau/tau forms (T181, pT181, pT181/T181, S202, pS202, pS202/S202, T217, pT217, pT217/T217).

    Blood collection

    Time frame: 6 months

  6. Measure changes of cerebrospinal fluid p-tau/tau forms (T181, pT181, S202, pS202, pS202/S202, T217, pT217, pT217/T217).

    CSF collection

    Time frame: 6 months

Other outcomes

  1. Measure changes of cerebrospinal TREM2 (exploratory)

    CSF

    Time frame: 6 months

  2. Measure changes of cerebrospinal NPTX2 (exploratory)

    CSF

    Time frame: 6 months

  3. Measure changes of cerebrospinal NfL (exploratory)

    CSF

    Time frame: 6 months

  4. Measure changes of blood plasma NfL (exploratory)

    Blood

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Washington University in St. Louis, School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Cristina Toedebusch, BS · Contacttoedebuschc@wustl.edu · 314-747-0646
    • Chloe Meehan, BS, MA · Contactcmeehan@wustl.edu · 314-273-0878
    • Brendan P. Lucey, M.D. · Principal investigator
    • J. Philip Miller, Ph.D. · Sub investigator
    • Jason Hassenstab, Ph.D. · Sub investigator
    • David Carr, M.D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2030, 72 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 72 months is above that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 23, 2024
StartActual
Mar 11, 2024
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06274528
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Mar 11, 2024
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Jul 13, 2026

Study contacts

Chloe Meehan, MA
Contact
cmeehan@wustl.edu
314-273-0878
Crirstina Toedebusch
Contact
toedebuschc@wustl.edu
314-747-0646
Brendan Lucey, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemborexant

Start the discussion